A patient with recalcitrant oral pemphigus vulgaris successfully treated with a biologic drug- Rituximab
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease affecting mucous membranes and the skin. Rituximab (RTX), a monoclonal antibody against CD20, has been approved by FDA for the treatment of adults with moderate to severe PV. A 42-year-old Indian woman, previously diagnosed with oral...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Online |
| Язык: | английский |
| Опубликовано: |
International Association for Dental Research (Nigeria Division)
2019
|
| Online-ссылка: | https://ajoh.oauife.edu.ng/index.php/ajoh/article/view/41 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Ваш комментарий будет первым!